Heart age estimated using explainable advanced electrocardiography

Thomas Lindow, MD, PhD^{1,2,3*}, Israel Palencia-Lamela,^{1,4*} Todd T Schlegel, MD^{5,6},
Martin Ugander, MD, PhD^{1,5}

1. Kolling Institute, Royal North Shore Hospital, and University of Sydney, Sydney, Australia
2. Department of Clinical Physiology, Research and Development, Växjö Central Hospital, Region Kronoberg, Sweden
3. Clinical Physiology, Clinical Sciences, Lund University, Sweden
4. Davidson College, Davidson, North Carolina, USA
5. Department of Clinical Physiology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden
6. Nicollier-Schlegel SARL, Trélex, Switzerland

**Shared first-authorship by equal contribution*

Fundings: TL is currently under the support of postdoctoral research grants from The Swedish Heart-Lung Foundation (grant no 20200553), the Swedish Cardiac Society, the Royal Swedish Academy of Sciences (grant no LM2019-0013), Women and Health Foundation, Region Kronoberg (grant no 8301), The Swedish Heart and Lung Association (grant no LKH1387), Swedish Association of Clinical Physiology, and the Scandinavian Society of Clinical Physiology; Nuclear Medicine. The study was funded in part by grants (PI Ugander) from New South Wales Health, Heart Research Australia, and the University of Sydney.

Author contributions: TL and IPL contributed to study design, performed the data analysis, wrote the first manuscript drafts, prepared the figures, and are shared first authors by equal contributions. TTS curated the data, contributed to study design, performed the prediction modeling, and critically revised the manuscript. MU designed the study, provided supervision, and critically revised the manuscript. All authors read and approved the final version of the manuscript.

Competing interests:

TL, IPL: None

TTS is owner and founder of Nicollier-Schlegel SARL, which performs ECG interpretation consultancy using software that can quantify the advanced ECG measures used in the current study. TTS and MU are owners and founders of Advanced ECG Systems, a company that is developing commercial applications of advanced ECG technology used in the current study.

Corresponding author: Martin Ugander, martin.ugander@ki.se, Professor of Cardiac Imaging, University of Sydney, Sydney, Australia, and Karolinska Institute, Sweden.

Background: Electrocardiographic (ECG) Heart Age conveying cardiovascular risk has been estimated by both Bayesian and artificial intelligence approaches. We hypothesized that explainable measures from the 10-second 12-lead ECG could successfully predict Bayesian ECG Heart Age.

Methods: Advanced analysis was performed on ECGs from healthy subjects and patients with cardiovascular risk or proven heart disease. Regression models were used to predict a Bayesian 5-minute ECG Heart Age from the standard resting 10-second 12-lead ECG. The difference between 10-second ECG Heart Age and chronological age was compared.

Results: In total, 2,771 subjects were included (n=1682 healthy volunteers, n=305 with cardiovascular risk factors, n=784 with cardiovascular disease). Overall, 10-second Heart Age showed strong agreement with the 5-minute Heart Age ($R^2=0.94$, $p<0.001$, mean $\pm$ SD bias 0.0 $\pm$ 5.1 years). The difference between 10-second ECG Heart Age and chronological age was 0.0 $\pm$ 5.7 years in healthy individuals, 7.4 $\pm$ 7.3 years in subjects with cardiovascular risk factors ($p<0.001$), and 14.3 $\pm$ 9.2 years for patients with cardiovascular disease ($p<0.001$).

Conclusions: ECG Heart Age can be accurately estimated from a 10-second 12-lead ECG in a transparent and explainable fashion based on known ECG measures, without artificial intelligence techniques. The difference between ECG Heart Age and chronological age increases markedly with cardiovascular risk and disease.

Keywords: vascular age; electrocardiography cardiovascular risk prediction; advanced electrocardiography; vectorcardiography

59

60

61 **Background**

62 Cardiovascular disease is a significant contributor to mortality, and pathological processes
63 begin early and can progress silently for many years¹⁻³. Many of the risk factors for
64 developing cardiovascular disease are lifestyle-related⁴. Fortunately, several of these are
65 modifiable, and risk can therefore be reduced for example by smoking cessation, dietary
66 changes and increased physical activity^{5,6}. To accomplish this, an individual must fully
67 understand their risk and become motivated to act upon it. One way of communicating risks
68 to the patient is to present the risk as a “Heart Age”, which can be contrasted to the patient’s
69 chronological age. A Heart Age can either be determined by translating risk factor scores to
70 what age that score would represent in an individual with no risk factors, or it can be based on
71 electrocardiographic changes⁷⁻¹². Describing the risk to the patient using Heart Age has been
72 reported to reduce metabolic risk factors and may have the advantage of being easily
73 understood by the patient^{11,13}. A similar approach has been applied when conveying risk to
74 smokers by describing how ‘old’ their lungs are, and such an approach increased the chance
75 of smoking cessation¹⁴.

76 Moving beyond but not excluding basic ECG measurements such as heart rate and waveform
77 amplitudes and durations, the diagnostic output from the ECG can be further substantially
78 improved by using combinations of advanced ECG measures from 12-lead-ECG-derived
79 vectorcardiography and waveform complexity¹⁵⁻¹⁷. An accurate ECG Heart Age using
80 advanced, 5-minute, 12-lead ECG was developed in 2014, based on Bayesian statistics⁹. The
81 Bayesian approach was transparent in so much as the advanced ECG measures contributing to
82 the ECG Heart Age were well-described. After being trained on a set of healthy individuals,
83 this approach yielded increased ECG Heart Ages for subjects at risk of cardiovascular disease
84 and even higher ECG Heart Ages for those with established cardiovascular disease⁹.
85 However, the reliance on 5-minute, high-fidelity 12-lead ECG recordings lessens the

likelihood of widespread clinical use. If standard 10-second ECG recordings could be used instead, the clinical impact might be enhanced. Moreover, artificial intelligence has been used to estimate ECG Heart Age using the 10-second resting 12-lead ECG^{7,8,10}. However, artificial intelligence techniques are limited by their “black box” approach, whereby the clinician does not have transparency as to the exact source(s) of the changes in the ECG that can affect an ECG Heart Age or other output^{18,19}. Therefore, the aim of the study was to predict 5-minute ECG Heart Age from measures available by 10-second 12-lead ECG, and to compare the 10-second ECG Heart Age to chronological age in healthy subjects, subjects with cardiovascular risk factors, and patients with established cardiovascular disease. We hypothesized that 10-second 12-lead ECG recordings could accurately predict Bayesian ECG Heart Ages derived from 5-minute 12-lead ECG recordings.

97

98 **Methods**

99 A database of de-identified patients with both 5-minute and 10-second 12-lead ECG
100 recordings was utilized for the study⁹. Within that database, healthy individuals, patients at
101 cardiovascular risk, and patients with established cardiovascular disease were included. All
102 healthy subjects were low-risk asymptomatic volunteers with absence of any cardiovascular
103 or systemic disease, based on clinical history and physical examination. Exclusion criteria for
104 the healthy subjects included increased blood pressure at physical examination ($\geq 140/90$ mm
105 Hg), treatment for hypertension or diabetes, or active smoking. Patients with established
106 cardiovascular disease were included based on the presence of either coronary heart disease
107 (determined by coronary angiography with at least one obstructed vessel ($\geq 50\%$) in at least
108 one major native coronary vessel or coronary graft, or, if coronary angiography was either
109 unavailable or clinically not indicated, one or more reversible perfusion defects on 99m-Tc-
110 tetrofosmin single-photon emission computed tomography (SPECT)²⁰⁻²²), left ventricular

hypertrophy (LVH) based on imaging evidence of at least moderate, concentric wall thickening according to guidelines of the American Society of Echocardiography²³, left systolic dysfunction (left ventricular ejection fraction $\leq 50\%$) at echocardiography, cardiac magnetic resonance imaging (CMR) or SPECT, or findings suggestive of dilated/hypertrophic/ischemic cardiomyopathy at echocardiography or CMR¹⁶. Finally, subjects at cardiovascular risk were included based on the presence of cardiovascular risk factors such as hypertension or diabetes but no confirmed established cardiovascular disease⁹.

Based on the above, three groups of study participants were included: healthy subjects, subjects at cardiovascular risk, and patients with established cardiovascular disease. By methodological design, only healthy subjects were initially included when considering optimal measures of ECG available from 10-second 12-lead ECG for predicting the 5-minute ECG Heart Age. The 10-second ECG measures considered for the prediction model included: (1) From the conventional ECG: heart rate, R-to-R, P-wave, PR, QRS, QT, QTc, and TQ interval durations, as well as the conventional ECG amplitudes and axes; (2) From the transformation of the 12-lead ECG to the Frank X, Y and Z lead vectorcardiogram (VCG) via Kors' transform²⁴⁻²⁸: the spatial means and peaks QRS-T angles, the spatial ventricular gradient and its individual QRS and T components, the spatial QRS- and T-wave axes (azimuths and elevations), waveform amplitudes and areas, including those in the three individual vectorcardiographic planes, and spatial QRS- and T-wave velocities; and (3) measures of QRS- and T-wave waveform complexity based on singular value decomposition after signal averaging²⁹⁻³¹.

For all study participants, the difference between the 10-second ECG Heart Age and the chronological age was also calculated. Results were then compared between the three groups defined above. All participants gave written informed consent. All recordings were obtained under Institutional Review Board (IRB) approvals from NASA's Johnson Space Center and

partner hospitals that fall under IRB exemptions for previously collected and de-identified data. The study was performed in accordance with the Declaration of Helsinki.

Statistical analysis

Continuous variables were described using mean and standard deviation (SD). The chi-squared test was used to test for proportional differences between groups. Student's *t* test was used to compare group means. The 10-second ECG Heart Age was first derived only in the healthy subject group through a process of feature selection, via optimized stepwise procedures, of measures available from 10-s, standard-fidelity ECG recordings, first using univariable linear regression, and finally as multivariable linear regression, to best predict the 5-minute ECG Heart Age⁹. The best model was defined as the model with highest R^2 value that was also the most parsimonious, i.e., a model with statistically equal performance that incorporated a lesser number of measures was considered more parsimonious due to less proneness to over-fitting. The best model from the healthy volunteers was then applied forward to an expanded population that also included the other two groups (cardiovascular risk and cardiovascular disease, respectively), while not changing any of the included variables, and only allowing optimization of the included coefficients. The final sex-specific model was then applied across all three groups as the 10-second ECG Heart Age, and comparisons with 5-minute ECG Heart Age are presented as scatter plots and Bland-Altman plots. A two-sided p-value of 0.05 was used as to define statistical significance. Statistical analyses were performed using SAS JMP version 11.0, SAS Institute Inc, Cary, NC, USA, and R version 3.5.3R, R Foundation for Statistical Computing, Vienna, Austria, <https://www.R-project.org/>.

Results

In total, 2,771 patients were included (n=1682 healthy volunteers, n=305 subjects with cardiovascular risk factors, n=784 with cardiovascular disease). Baseline characteristics are presented in Table 1. The ECG measures included in the final prediction models are presented in Table 2 (males) and Table 3 (females).

The 10-second ECG Heart Age showed excellent agreement with the 5-minute Heart Age ($R^2=0.94$, $p<0.001$, mean $\pm$ SD bias 0.0 $\pm$ 5.2 years), Figure 1. Agreement was strong for both males and females ($R^2=0.91$, $p<0.001$, and $R^2=0.92$, $p<0.001$ respectively). In healthy subjects, there was no difference in ECG Heart Age and chronological age (0.0 $\pm$ 5.7 years). In subjects with cardiovascular risk factors, the difference was higher (7.4 $\pm$ 7.3 years, $p<0.001$). Patients with cardiovascular disease showed the largest difference between ECG Heart Age and chronological age (14.3 $\pm$ 9.2 years, $p<0.001$ when compared to subjects at cardiovascular risk), Figure 2.

Discussion

We found that ECG Heart Age based on measures of advanced ECG can be accurately predicted from standard resting 10-second 12-lead ECG recordings. This facilitates widespread use of ECG Heart Age in routine clinical settings, since neither specialized ECG machines nor unusually lengthy recordings are necessary. Also, if digital ECG raw data are available and the recording is of acceptable quality, ECG Heart Age can be retrospectively determined. Further, we found ECG Heart Age to be similar to chronological age in healthy individuals, while the ECG Heart Age was increasingly older with increasing cardiovascular disease status. This suggests that the ECG Heart Age is likely to provide accurate cardiovascular risk prediction, although validation in other datasets is necessary.

Explainability and transparency of variables that contribute to ECG Heart Age

For an estimation of Heart Age to be accurate in predicting an age that is similar to the chronological age when the heart is healthy, and increased when the heart is diseased, it is desirable that the included ECG measures change with age, and that the change is augmented with increasing cardiovascular risk or disease severity. Beyond age itself, the two ECG measures that had the strongest influence (highest t ratio) on the model were P-wave duration and spatial QT duration, and these measures fit this description well. P-wave duration increases with age³², and increased P-wave duration can be seen in advanced cardiovascular pathologies, e.g. heart failure and cardiac amyloidosis³³. Similarly, QT duration increases with age³⁴. Further, QT prolongation is associated with increased of cardiovascular risk, even beyond the rare long QT syndromes³⁵, and with incrementally increased risk in advanced ages³⁶. These general characteristics are also true for increased heart rate and for leftward shifting of the frontal plane QRS axis³⁷⁻⁴⁰. The other measures included in the score track changes in the vectorcardiographic QRS and T, and in T-wave complexity by singular value decomposition. Such changes are also known to occur in conditions associated with increased cardiovascular risk, such as hypertension and diabetes⁴¹, and in established cardiovascular disease, in which they often provide strong diagnostic and prognostic information^{24-27,29-31}. Notably, these changes are not easily detectable by visual interpretation of a standard 12-lead ECG. How these ECG measures can affect the ECG Heart Age is exemplified in Figure 3. Taken together, the described ECG measures that contribute in a multivariable fashion to the ECG Heart Age all have physiologically reasonable associations with age and disease in a way that is transparent to the assessing clinician, thus providing important explainability to the model.

Differences compared to Bayesian 5-minute ECG Heart Age

The original, Bayesian 5-minute ECG Heart Age requires information from measures of beat-to-beat heart rate and QT variability,⁹ and of the root-mean square voltage or other aspects of high-frequency (high fidelity) components of the QRS complex⁴²⁻⁴⁴. However, 10-second-duration recordings of standard fidelity do not allow for such measures, and therefore they were not included in the 10-second ECG Heart Age. However, unlike the original Bayesian 5-minute ECG Heart Age, the 10-second ECG Heart Age should be derivable from any standard 12-lead ECG machine, as long as it is sufficiently equipped with software that can measure the included measures and calculate the 10-second ECG Heart Age. The presented 10-second ECG Heart Age might therefore be anticipated to contribute to more widespread clinical penetration and use.

Comparison with other Heart (or Vascular) Ages

Different means of expressing cardiovascular risk by translating it into a heart or vascular age have recently been published¹³. Attia, et al, showed that by using a deep neural network (DNN) artificial intelligence (AI) technique, a patient's chronological age could be predicted, and that if the difference between the predicted and actual age was small, prognosis was good⁸. When Heart Age by Attia et al's technique was older than the chronological age, the risk of future death was increased⁷. This corresponds well to the findings in our study that ECG Heart Age increased with increasing burden of cardiovascular risk. However, the prognostic value of the ECG Heart Age presented in the current study requires additional validation. Furthermore, another AI method similar to that of Attia et al reported similarly encouraging results¹⁰. However, although the results of such AI studies are promising, DNN-based AI techniques are inherently problematic in several respects, especially in relation to their lack of transparency and explainability, i.e., the 'black box' of AI^{18,19}. Without the ability to know the

exact features of the 12-lead ECG that are most important in a given DNN model's output, both interpretability and ethical accountability are compromised⁴⁵. Moreover, it is effectively impossible for a clinician to identify, when critically evaluating the diagnostic output of a DNN-based AI model, the possible contribution to the result from methodological artifact or bias merely related to noise or to differing technical specifications between different ECG machines⁴⁶. Alternatively, it is not possible to know if unanticipated results are possibly just related to excess dependency on the particular characteristics of a given DNN AI model's training set⁴⁷. In addition, a major flaw in both DNN-based AI models is that the age predictions were made using datasets including individuals with both cardiovascular risk factors and established disease^{8,10}. For ECG Heart Age to be used as a marker of cardiovascular risk, it is imperative that ECG Heart Age agrees with chronological age in healthy populations, since it is the deviations from the line of identity in this relationship that form the basis of the assumed risk increase⁸. Hence, we believe that the pursuit of an ECG Heart Age developed from heart-healthy subjects of varying ages, but without a black-box DNN or related AI methodology is valuable, and that the present results provide sufficient confirmation of accuracy to encourage further development. In addition, models in which the assessments were based on age predictions in healthy subjects will likely outperform models that were not. And finally, the use of more transparent regression models will also increase the ability of clinicians to better understand the origin of any unexpected result, and to thereafter relay it to the patient with a more convincing sense of trust and ethical accountability⁴⁵.

Limitations

Using the same dataset for training and validation, our results can only be considered as proof-of-concept. Although the difference between ECG Heart Age and the subjects'

chronological age increased with increasing cardiovascular risk and/or disease, the prognostic value is unknown. Also, although ECG Heart Age was highly accurate, the precision cannot be reliably defined in this study. These aspects therefore need to be addressed in future studies.

Conclusion

We show that ECG Heart Age can be accurately, transparently, and explainably estimated from a standard 10-s, resting 12-lead ECG utilizing multiple, discrete conventional and advanced ECG measures. The difference between ECG Heart Age and subjects' chronological age increases with increasing cardiovascular risk and disease. The prognostic value of our transparent and explainable 10-second ECG Heart Age requires prospective evaluation in future studies.

References

- 1 Bergström, G. *et al.* Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. *Circulation* **144**, 916-929, doi:10.1161/circulationaha.121.055340 (2021).
- 2 Townsend, N. *et al.* Cardiovascular disease in Europe: epidemiological update 2016. *Eur Heart J* **37**, 3232-3245, doi:10.1093/eurheartj/ehw334 (2016).
- 3 Badimon, L. & Vilahur, G. Thrombosis formation on atherosclerotic lesions and plaque rupture. *J Int Med* **276**, 618-632, doi:10.1111/joim.12296 (2014).
- 4 Andersson, C. & Vasan, R. S. Epidemiology of cardiovascular disease in young individuals. *Nat Rev Cardiol* **15**, 230-240, doi:10.1038/nrcardio.2017.154 (2018).
- 5 Elliot, C. A. & Hamlin, M. J. Combined diet and physical activity is better than diet or physical activity alone at improving health outcomes for patients in New Zealand's primary care intervention. *BMC Publ Health* **18**, 230, doi:10.1186/s12889-018-5152-z (2018).
- 6 Lim, S. S. *et al.* A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* **380**, 2224-2260, doi:10.1016/s0140-6736(12)61766-8 (2012).
- 7 Ladejobi, A. O. *et al.* The 12-lead electrocardiogram as a biomarker of biological age. *Eur Heart J - Dig Health* **2**, 379-389, doi:10.1093/ehjdh/ztac043 (2021).
- 8 Attia, Z. I. *et al.* Age and Sex Estimation Using Artificial Intelligence From Standard 12-Lead ECGs. *Circ Arrhythm Electrophysiol* **12**, e007284, doi:10.1161/circep.119.007284 (2019).

- 296 9 Ball, R. L., Feiveson, A. H., Schlegel, T. T., Starc, V. & Dabney, A. R. Predicting
297 "heart age" using electrocardiography. *J Pers Med* **4**, 65-78, doi:10.3390/jpm4010065
298 (2014).
- 299 10 Lima, E. M. *et al.* Deep neural network-estimated electrocardiographic age as a
300 mortality predictor. *Nature Commun* **12**, 5117, doi:10.1038/s41467-021-25351-7
301 (2021).
- 302 11 Lopez-Gonzalez, A. A. *et al.* Effectiveness of the Heart Age tool for improving
303 modifiable cardiovascular risk factors in a Southern European population: a
304 randomized trial. *Eur J Prev Cardiol* **22**, 389-396, doi:10.1177/2047487313518479
305 (2015).
- 306 12 Soureti, A., Hurling, R., Murray, P., van Mechelen, W. & Cobain, M. Evaluation of a
307 cardiovascular disease risk assessment tool for the promotion of healthier lifestyles.
308 *Eur J Cardiovasc Prev Rehab* **17**, 519-523, doi:10.1097/HJR.0b013e328337ccd3
309 (2010).
- 310 13 Groenewegen, K. A. *et al.* Vascular age to determine cardiovascular disease risk: A
311 systematic review of its concepts, definitions, and clinical applications. *Eur J Prev*
312 *Cardiol* **23**, 264-274, doi:10.1177/2047487314566999 (2016).
- 313 14 Parkes, G., Greenhalgh, T., Griffin, M. & Dent, R. Effect on smoking quit rate of
314 telling patients their lung age: the Step2quit randomised controlled trial. *BMJ* **336**,
315 598-600, doi:10.1136/bmj.39503.582396.25 (2008).
- 316 15 Maanja, M. *et al.* The electrical determinants of increased wall thickness and mass in
317 left ventricular hypertrophy. *J Electrocardiol* **58**, 80-86,
318 doi:10.1016/j.jelectrocard.2019.09.024 (2020).
- 319 16 Schlegel, T. T. *et al.* Accuracy of advanced versus strictly conventional 12-lead ECG
320 for detection and screening of coronary artery disease, left ventricular hypertrophy and

321 left ventricular systolic dysfunction. *BMC Cardiovasc Disord* **10**, 28,
322 doi:10.1186/1471-2261-10-28 (2010).

323 17 Johnson, K. *et al.* Advanced Electrocardiography Identifies Left Ventricular Systolic
324 Dysfunction in Non-Ischemic Cardiomyopathy and Tracks Serial Change over Time. *J*
325 *Cardiovasc Dev Dis* **2**, 93-107, doi:10.3390/jcdd2020093 (2015).

326 18 Gladding, P. A., Hewitt, W. & Schlegel, T. T. Going deep with ecg and aortic
327 stenosis: Touchdown or incomplete pass? *J Am Heart Assoc* **9**, e016193-e016193,
328 doi:10.1161/JAHA.120.016193 (2020).

329 19 The Lancet Respiratory Medicine, L. R. M. Opening the black box of machine
330 learning. *Lancet Respir Med* **6**, 801-801, doi:10.1016/S2213-2600(18)30425-9 (2018).

331 20 Vrtovec, B., Sinkovec, M., Starc, V., Radovancevic, B. & Schlegel, T. T. Coronary
332 artery disease alters ventricular repolarization dynamics in type 2 diabetes. *Pacing*
333 *Clin Electrophysiol* **28 Suppl 1**, S178-181, doi:10.1111/j.1540-8159.2005.00076.x
334 (2005).

335 21 Persson, E., Carlsson, M., Palmer, J., Pahlm, O. & Arheden, H. Evaluation of left
336 ventricular volumes and ejection fraction by automated gated myocardial SPECT
337 versus cardiovascular magnetic resonance. *Clin Physiol Funct Imaging* **25**, 135-141,
338 doi:10.1111/j.1475-097X.2005.00599.x (2005).

339 22 Trägårdh, E. *et al.* High-frequency electrocardiogram analysis in the ability to predict
340 reversible perfusion defects during adenosine myocardial perfusion imaging. *J*
341 *Electrocardiol* **40**, 510-514, doi:10.1016/j.jelectrocard.2007.03.242 (2007).

342 23 Lang, R. M. *et al.* Recommendations for cardiac chamber quantification by
343 echocardiography in adults: an update from the American Society of
344 Echocardiography and the European Association of Cardiovascular Imaging. *Eur*
345 *Heart J Cardiovasc maging* **16**, 233-270, doi:10.1093/ehjci/jev014 (2015).

346 24 Yamazaki, T., Froelicher, V. F., Myers, J., Chun, S. & Wang, P. Spatial QRS-T angle
347 predicts cardiac death in a clinical population. *Heart rhythm* **2**, 73-78,
348 doi:10.1016/j.hrthm.2004.10.040 (2005).

349 25 Fayn, J., Rubel, P., Pahlm, O. & Wagner, G. S. Improvement of the detection of
350 myocardial ischemia thanks to information technologies. *Int J Cardiol* **120**, 172-180,
351 doi:10.1016/j.ijcard.2006.09.025 (2006).

352 26 Kardys, I. *et al.* Spatial QRS-T angle predicts cardiac death in a general population.
353 *European heart journal* **24**, 1357-1364, doi:10.1016/S0195-668X(03)00203-3 (2003).

354 27 Horinaka, S. *et al.* Ventricular gradient variability. New ECG method for detection of
355 ischemic heart disease. *J Electrocardiol* **28**, 177-183, doi:10.1016/S0022-
356 0736(05)80255-9 (1995).

357 28 Kors, J. A., van Herpen, G., Sittig, A. C. & van Bommel, J. H. Reconstruction of the
358 Frank vectorcardiogram from standard electrocardiographic leads: diagnostic
359 comparison of different methods. *Eur Heart J* **11**, 1083-1092 (1990).

360 29 Zabel, M. *et al.* Analysis of T-wave morphology from the 12-lead electrocardiogram
361 for prediction of long-term prognosis in male US veterans. *Circulation* **105**, 1066-
362 1070, doi:10.1161/hc0902.104598 (2002).

363 30 Okin, P. M. *et al.* Repolarization Abnormality for Prediction of All-Cause and
364 Cardiovascular Mortality in American Indians: The Strong Heart Study. *J Cardiovasc*
365 *Electrophysiol* **16**, 945-951, doi:10.1111/j.1540-8167.2005.40808.x (2005).

366 31 Priori, S. G. *et al.* Evaluation of the spatial aspects of T-wave complexity in the long-
367 QT syndrome. *Circulation* **96**, 3006-3012, doi:10.1161/01.CIR.96.9.3006 (1997).

368 32 Chhabra, L., Devadoss, R., Chaubey, V. K. & Spodick, D. H. Interatrial Block in the
369 Modern Era. *Curr Cardiol Rev* **10**, 181-189,
370 doi:10.2174/1573403X10666140514101748 (2014).

371 33 Lindow, T. & Lindqvist, P. The Prevalence of Advanced Interatrial Block and Its
372 Relationship to Left Atrial Function in Patients with Transthyretin Cardiac
373 Amyloidosis. *J Clin Med* **10**, doi:10.3390/jcm10132764 (2021).

374 34 Rautaharju, P. M., Mason, J. W. & Akiyama, T. New age- and sex-specific criteria for
375 QT prolongation based on rate correction formulas that minimize bias at the upper
376 normal limits. *Int J Cardiol* **174**, 535-540, doi:10.1016/j.ijcard.2014.04.133 (2014).

377 35 Shah, S. R., Park, K. & Alweis, R. Long QT Syndrome: A Comprehensive Review of
378 the Literature and Current Evidence. *Curr Prob Cardiol* **44**, 92-106,
379 doi:10.1016/j.cpcardiol.2018.04.002 (2019).

380 36 Nielsen, J. B. *et al.* Risk prediction of cardiovascular death based on the QTc interval:
381 evaluating age and gender differences in a large primary care population. *Eur Heart J*
382 **35**, 1335-1344, doi:10.1093/eurheartj/ehu081 (2014).

383 37 Goorakani, Y. *et al.* Correlation of resting heart rate with anthropometric factors and
384 serum biomarkers in a population-based study: Fasa PERSIAN cohort study. *BMC*
385 *Cardiovas Disord* **20**, 319-319, doi:10.1186/s12872-020-01594-y (2020).

386 38 Ogliari, G. *et al.* Resting heart rate, heart rate variability and functional decline in old
387 age. *Can Med Assoc J* **187**, E442-e449, doi:10.1503/cmaj.150462 (2015).

388 39 Morcet, J. F., Safar, M., Thomas, F., Guize, L. & Benetos, A. Associations between
389 heart rate and other risk factors in a large French population. *J Hyperten s* **17**, 1671-
390 1676, doi:10.1097/00004872-199917120-00003 (1999).

391 40 Evans, J. G., Prior, I. A. & Tunbridge, W. M. Age-associated change in QRS axis:
392 intrinsic or extrinsic ageing? *Gerontology* **28**, 132-137, doi:10.1159/000212523
393 (1982).

- 394 41 Bergfeldt, L. *et al.* Spatial peak and mean QRS-T angles: A comparison of similar but
395 different emerging risk factors for cardiac death. *J Electrocardiol***61**, 112-120,
396 doi:10.1016/j.jelectrocard.2020.05.013 (2020).
- 397 42 Ringborn, M. M. D. *et al.* Comparison of high-frequency QRS components and ST-
398 segment elevation to detect and quantify acute myocardial ischemia. *J Electrocardiol*
399 **43**, 113-120, doi:10.1016/j.jelectrocard.2009.11.009 (2010).
- 400 43 Trägårdh, E., Pahlm, O., Wagner, G. S. & Pettersson, J. Reduced high-frequency QRS
401 components in patients with ischemic heart disease compared to normal subjects. *J*
402 *Electrocardiol* **37**, 157-162, doi:10.1016/j.jelectrocard.2004.02.004 (2004).
- 403 44 Schlegel, T. T. *et al.* Real-Time 12-Lead High-Frequency QRS Electrocardiography
404 for Enhanced Detection of Myocardial Ischemia and Coronary Artery Disease. *Mayo*
405 *Clin Proc* **79**, 339-350, doi:10.4065/79.3.339 (2004).
- 406 45 Yoon, C. H., Torrance, R. & Scheinerman, N. Machine learning in medicine: should
407 the pursuit of enhanced interpretability be abandoned? *J Med Ethics*,
408 doi:10.1136/medethics-2020-107102 (2021).
- 409 46 Brisk, R. *et al.* The effect of confounding data features on a deep learning algorithm to
410 predict complete coronary occlusion in a retrospective observational setting. *Eur*
411 *Heart J - Dig Health* **2**, 127-134, doi:10.1093/ehjdh/ztab002 (2021).
- 412 47 Siontis, K. C. *et al.* Use of Artificial Intelligence Tools Across Different Clinical
413 Settings: A Cautionary Tale. *Circ Cardiovasc Qual Outcomes***14**, e008153,
414 doi:10.1161/circoutcomes.121.008153 (2021).

415

416

417

Table 1. Baseline characteristics

	All (n=2,771)	Healthy (n=1,682)	Subjects at CV risk (n=305)	Patients with CV disease (n=784)	p
Age, years	46.2 (16.0)	38.6 (13.0)	54.8 (11.2)	59.0 (13.2)	<0.001
Male sex, n (%)	1645 (59.4)	999 (59.4)	163 (53.4)	483 (61.6)	0.048
5-minute ECG Heart Age, years	51.1 (21.7)	38.3 (14.1)	61.9 (13.2)	74.2 (15.6)	<0.001
CAD, n (%)	421 (15.2)	-	-	421 (53.7)	-
ICM, n (%)	120 (4.3)	-	-	120 (15.3)	-
HCM, n (%)	92 (3.3)	-	-	92 (11.7)	-
LVH, n (%)	96 (3.5)	-	-	96 (12.2)	-
NICM, n (%)	53 (1.9)	-	-	53 (6.8)	-

Age and 5-minute ECG Heart Age are presented as mean (standard deviation).

Abbreviations: CAD: coronary artery disease; ICM: ischemic cardiomyopathy; HCM: hypertrophic cardiomyopathy; LVH: left ventricular hypertrophy; NICM: non-ischemic cardiomyopathy

418

419

420

421

422

423

424

425

426

427

428

429

430

Table 2. Measures included in the 10-second ECG Heart Age (male patients)

Measure	Estimate	Standard error	t ratio
<i>(Intercept)</i>	-60.575	2.353	-25.73
Age, years	0.820	0.007	113.73
P-wave duration, ms	0.288	0.007	39.99
Spatial QT interval, ms	0.081	0.004	22.86
Heart rate, min ⁻¹	0.242	0.012	20.02
QRS max amplitude in VCG lead Y, μ V	-0.007	0.000	-18.20
Frontal plane QRS axis, radians	-5.834	0.395	-14.75
T-wave complexity, $\text{Ln} \sum(\text{EV3:8}) / (\text{EV1}-\text{EV2})$, unitless	2.152	0.164	13.12
Spatial ventricular gradient minus Spatial mean QRS, mV*s	-55.841	4.464	-12.51
Male sex (value=1)	1.996	0.215	9.27
QRS RMS in VCG vector magnitude lead, mV	10.315	1.612	6.40
QRS average spatial velocity in VCG vector magnitude lead, mV/s	0.106	0.017	6.30
Portion of QRS loop in posterior superior quadrant of left sagittal plane by VCG, %	0.033	0.009	3.55

Abbreviations: Ln: Natural logarithm; EV: Eigenvalues; VCG: vectocardiographic; RMS: root mean square

Table 3. Measures included in the 10-second ECG Heart Age (female patients)

Measure	Estimate	Standard error	t ratio
<i>(Intercept)</i>	-70.477	2.662	-26.47
Age, years	0.850	0.008	104.26
P-wave duration, ms	0.331	0.008	40.73
Spatial QT interval, ms	0.095	0.004	23.58
Heart rate, min ⁻¹	0.281	0.014	20.57
QRS max amplitude in VCG lead Y, μ V	-0.009	0.000	-18.54
Frontal plane QRS axis, radians	-6.354	0.447	-14.21
Spatial ventricular gradient minus Spatial mean QRS, mV*s	-67.642	5.049	-13.40
T-wave complexity, $\text{Ln} \sum(\text{EV}3:8) / (\text{EV}1-\text{EV}2)$, unitless	2.359	0.185	12.72
QRS RMS in VCG vector magnitude lead, mV	11.701	1.822	6.42
QRS average spatial velocity in VCG vector magnitude lead, mV/s	0.116	0.019	6.10
Portion of QRS loop in posterior superior quadrant of left sagittal plane by VCG, %	0.034	0.010	3.22

Abbreviations: Ln: Natural logarithm; EV: Eigenvalues; VCG: vectocardiographic; RMS: root mean square

432

433

434

435

436

437

438

Figure 1. Left panel: Scatter plot showing the relation between the 10-second ECG Heart Age and the 5-minute ECG Heart Age in all participants. The R^2 value was 0.94 ($p < 0.001$). Right panel: Bland-Altman plot showing the difference between the 10-second and 5-minute ECG Heart Age in relation to the mean of both ECG Heart Ages. The agreement between methods is strong, with minimal deviation from the identity line (dashed) or bias (0.0 ± 5.2 years).

Figure 2.

Panel A: The difference between the 10-second ECG Heart Age and chronological age in healthy subjects (left, dark green), subjects at cardiovascular (CV) risk (middle, light blue), and patients with CV disease (right, yellow). On average, there is no difference between ECG Heart Age and chronological age in healthy subjects. ECG Heart Age is higher in subjects at CV risk, and highest for those with overt CV disease.

Panel B: Scatter plots showing the relationship between the 10-second ECG Heart Age and chronological age in healthy subjects (left, dark green), subjects at CV risk (middle, light blue), and patients with CV disease (right, yellow). The dashed diagonal line is the identity line, i.e. indicating no difference between ECG Heart Age and chronological age.

Figure 3. Example of the transparency and explainability of the ECG Heart Age from two subjects with equal chronological age but different ECG Heart Ages, illustrated by a commensurately aged female heart, but a disproportionately aged male heart. The ECG measures for each of the two patients are shown in the table in the middle of the figure, presented in the order of the relative strength (strongest first, based on t ratio [not shown]) of contribution to the ECG Heart Age. Notably, P-wave duration is markedly different between these two patients, and heart rate is higher for the male than the female, helping drive the ECG Heart Age higher in the male. The R-wave amplitude in lead Y is also much larger in the

464 female, and the difference between the spatial ventricular gradient and the spatial mean QRS
465 in the female is also larger, likely due to preserved T-wave amplitudes, contributing to her
466 relatively younger ECG Heart Age. Furthermore, likely due to ischemic myocardial injuries,
467 T-wave complexity is increased in the male, suggesting that increased myocardial
468 repolarization heterogeneity also contributes to driving ECG Heart Age higher in the male, in
469 spite of his shorter QT interval.

A

B

60-year old, healthy female
without cardiovascular
risk factors or medications

60-year old male with
heart failure following
myocardial infarction

ECG measures

P-wave duration	90 ms	148 ms
Spatial QT interval	447 ms	380 ms
Heart rate	55/min	70/min
QRS max amplitude in VCG lead Y	835 μ V	299 μ V
Frontal plane QRS axis	0.58 radians	0.64 radians
Spatial ventricular gradient - spatial mean QRS	0.038 mV*s	0.003 mV*s
T-wave complexity, Ln	-1.92	1.21
QRS RMS in VCG vector magnitude lead	0.43 mV	0.31 mV
QRS average spatial velocity in vector magnitude lead	39.1 mV/s	23.5 mV/s
Portion of QRS loop in posterior superior quadrant of left sagittal plane by VCG	12.7%	25.2%

ECG HEART AGE

60 years

79 years